Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | USP1 | O94782 | 10/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BRS3 | P32247 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20929496 | 0.80 | NOTUM (0.38) | NOTUMPI4KBALDH1A1LMNA | |
| SCHEMBL17758799 | 0.80 | LMNA (0.46) | NOTUMMAPTPI4KBALDH1A1LMNA | |
| SCHEMBL20929258 | 0.78 | POLB (0.36) | POLBNOTUMUSP1METPCSK9 | |
| SCHEMBL17758747 | 0.78 | NOTUM (0.51) | NOTUMMAPTALDH1A1BRS3LMNA | |
| SCHEMBL14961826 | 0.74 | POLB (0.47) | POLBNOTUMMAPTALDH1A1LMNA | |
| SCHEMBL17758803 | 0.72 | MAPT (0.41) | POLBUSP1MAPTPI4KBALDH1A1 | |
| SCHEMBL20929257 | 0.71 | POLB (0.32) | POLBNOTUM | |
| SCHEMBL17758862 | 0.71 | POLB (0.43) | POLBLMNA | |
| SCHEMBL23352194 | 0.71 | LMNA (0.44) | NOTUMMAPTALDH1A1LMNA | |
| SCHEMBL17758865 | 0.70 | IDH1 (0.38) | POLBNOTUMUSP1METPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459321-B2 | Broad spectrum antiviral compositions and methods | EVRYS BIO, LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-20210139475-A1 | Broad Spectrum Antiviral Compositions and Methods | EVRYS BIO, LLC (US) | 2021-05-13 | — | — | US | disclosed |
| WO-2019079519-A1 | BROAD SPECTRUM ANTIVIRAL COMPOSITIONS AND METHODS | FORGE LIFE SCIENCE, LLC (US) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459321-B2 | Broad spectrum antiviral compositions and methods | IRF3, MAVS, ZC3HAV1 | POLB 1614/4885NOTUM 3929/4885USP1 2693/4885 |
| US-20210139475-A1 | Broad Spectrum Antiviral Compositions and Methods | MAVS, IRF3, ZC3HAV1 | POLB 1405/4885NOTUM 3824/4885USP1 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.